Article Text

PDF
THU0580 What are the patients' issues and needs related to their biologics (BDMARDS) and methotrexate (MTX) treatment in daily life: a quantitative cross-sectional survey among 344 patients to develop an educational smartphone app
  1. C Beauvais1,
  2. S Tropé2,
  3. A Lafourcade3,
  4. D Carnet4,
  5. L Grange5,
  6. L Carton6,
  7. D Lafarge7,
  8. G Montagu8,
  9. T Pham9,
  10. F Tubach10,
  11. J Sellam11,
  12. on behalf of Therapeutic education section of the French Society of Rheumatology and Club Rhumatismes Inflammation
  1. 1Rheumatology, Saint Antoine Hospital. APHP, Paris
  2. 2Association ANDAR, Montpellier
  3. 3Biostatistics, AP-HP Hôpital Pitié-Salpétrière, Paris
  4. 4ANDAR, Montpellier
  5. 5Rheumatology, Echirolles
  6. 6Association AFLAR
  7. 7Association AFS
  8. 8Unknowns, Strategic and Innovation Consulting, Paris
  9. 9Rheumatology, Hôpital Sainte-Marguerite, AP-HM, Marseille
  10. 10Biostatistics, Public Health, and Medical Information, AP-HP Hôpital Pitié-Salpétrière
  11. 11Reumatology, AP-HP St-Antoine, Univ Paris 06, Paris, France

Abstract

Background MTX and bDMARDs are the core treatments of chronic inflammatory arthritis (IA). We lack information on the patients' problems and needs in daily life, particularly on safety issues.

Objectives 1-collect the most frequent issues 2-explore the patients' perceptions on a dedicated smartphone application (SP App) 3) determine the profile of the patients interested.

Methods The survey was conducted on line. The questionnaire was designed by rheumatologists, methodologists, anthropologists, members of patients association (AP) and included 1-a non-exhaustive list of potential issues in daily life (fever, vaccines, ...) and practical aspects 2-a list of potential use of the App 3- free opinions 4- Two self-administrated questionnaire to test patients' knowledge on bDMARDs [1] and MTX [2].

Results The survey was carried out from June to August 2016 on the websites of the PA. Non-associative patients were recruited by 3 rheumatologists who provided the Internet link. 344 patients responded, 331 analyzed, 83% female, 50% had rheumatoid arthritis, 40% had spondyloarthritis, mean age 53 years, 60% were AP; 67% were treated with MTX, 70% had bDMARDs, 34% had MTX- bDMARDs combotherapy.

66% of patients reported problems; 67% had needed help or advice. The main issues were infections (27%), vaccines (13%), surgery (10%), dental care (7%), self-administration (6%), conservation/travelling (9%) and skipped doses (5%).

Among the 76% patients who have a SP, 80% use Apps and 32% Apps for their health. Among users, 87% patients would find an App useful to manage their treatment (36% rather agree and 51% strongly agree), 82% for symptoms requiring to stop their treatment, 93% for situations related to safety, 80% as a reminder of their treatment, 80% to know what to do in case of a skipped dose, 77% to have a safety checklist before treatment administration, 66% to recall the modalities of self-injections. Patients interested in the App are younger (p<0.05) non-associative (p<0.05) and live in medium-sized cities (p<0.01). No correlation was found with other sociodemographic characteristics, level of education, type/duration of arthritis or knowledge.

Conclusions Two-third of patients with arthritis face issues related to their treatment especially in case of infections, vaccination, surgery and travelling. A dedicated App is considered useful by 87% patients who already have a SP. The potential use of the App may improve safety, adherence and self-management in daily life.

References

  1. Gossec L et coll. Joint Bone Spine. 2013; Fayet F et coll J Clin Nurs. 2016.

References

Acknowledgements Grant: French Society of Rheumatology with the institutional funding by Biogen, Nordic Pharma, Roche.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.